Previous 10 | Next 10 |
Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharm...
Shares of Atea Pharmaceuticals (NASDAQ: AVIR) fell by as much as 14.4% in premarket trading Wednesday morning. The biotech's shares are sliding today in response to Roche 's (OTC: RHHBY) decision to terminate its involvement in the development of the oral COVID-19 therap...
With a loss of ~14.0% in early hours, Atea (NASDAQ:AVIR) continues to trade lower in reaction to the company’s post-close announcement on Wednesday that Swiss pharma giant Roche (OTCQX:RHHBY) is ending its partnership for the development of COVID-19 pill AT-527. Commenti...
Roche (OTCQX:RHHBY) and Atea Pharmaceutical (NASDAQ:AVIR) are ending a collaboration on the COVID-19 treatment AT-527. Rights to the candidate will be returned to Atea. The collaboratiopn officially ends on Feb. 10, 2022. Atea said it has the financial resources to continue the phase 3 trial ...
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roch...
Established COVID-19 vaccine makers have come under pressure after Pfizer (NYSE:PFE) and a United Nations-backed public health organization announced a licensing pact to allow generic-drugmakers to produce cheaper versions of the company’s experimental COVID-19 pill. Moderna (NASD...
Image source: The Motley Fool. Atea Pharmaceuticals Inc (NASDAQ: AVIR) Q3 2021 Earnings Call Nov 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Atea Pharmaceuticals Inc (AVIR) Q3 2021 Earnings Call Transcript ...
Atea Pharmaceuticals, Inc. (AVIR) Q3 2021 Earnings Conference Call November 11, 2021 16:30 ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman & Chief Executive Officer Janet Hammond -...
Atea Pharmaceuticals (NASDAQ:AVIR): Q3 GAAP EPS of -$0.34 misses by $0.17. Revenue of $32.8M misses by $20.66M. Press Release For further details see: Atea Pharmaceuticals EPS misses by $0.17, misses on revenue
Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data Demonstrate AT-527’s Rapid and Potent Antiviral Activity Against COVID-19 in Phase 2 ...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...